Marinus Pharmaceuticals (NASDAQ:MRNS) Earns “Overweight” Rating from Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $13.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the stock. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, September 18th. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Truist Financial reissued a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. JMP Securities restated a “market outperform” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Stock Down 1.8 %

Shares of NASDAQ:MRNS opened at $1.63 on Tuesday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. Marinus Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $11.26. The business’s 50 day simple moving average is $1.38 and its two-hundred day simple moving average is $2.73. The firm has a market cap of $89.54 million, a P/E ratio of -0.62 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the prior year, the business earned ($0.61) earnings per share. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MRNS. Hussman Strategic Advisors Inc. increased its position in shares of Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the last quarter. AQR Capital Management LLC grew its stake in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the period. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $28,000. SG Americas Securities LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth $34,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Marinus Pharmaceuticals in the 1st quarter worth about $384,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.